Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events

Pharmacotherapy

Volumn 27, Issue 2, 2007, Pages 207-217

  Sherer, Jeffrey T ^a   Adamus, Andrea T ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bisphosphonates; Oncology; Outcomes; Pamidronate; Prostate cancer; Skeletal related events; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COHORT STUDIES; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846804458     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.2.207     Document Type: Article

References (29)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate cancer. Cancer 2000;88:2989-94.
3. Berruttti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164:1248-53.
4. Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer 1997;79:545-50.
5. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439-44.
6. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropic-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136-9.
7. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004;32:290-2.
8. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
9. Mundy GR. Mechanisms of bone metastases. Cancer 1997;80:1546-56.
10. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
11. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urology 2003;169:2008-12.
12. Food and Drug Administration. Drugs approved in 1991. Available from www.fda.gov/bbs/topics/ANSWERS/ANS00372.html. Accessed December 1, 2004.
13. Novartis Pharmaceuticals Corporation. Aredia (pamidronate) package insert. East Hanover, NJ; 2004.
14. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
15. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
16. Hortobagyi GN, Theriault RL, Porter L, et al. for the Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
17. Hortobagyi GN, Theriault RL, Lipton A, et al, for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44.
18. Theriault RL, Lipton A, Hortobagyi GN, et al, for the Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-54.
19. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up from two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
20. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84.
21. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledrohic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9:2394-9.
22. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic carcinoma. J Natl Cancer Inst 2002;94:1458-68.
23. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
24. Berenson JR, Hillner BE, Kyle RA, et al. American College of Clinical Oncologists clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
25. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57.
26. National Comprehensive Cancer Network. Prostate cancer version 1.2004. Available from www.nccn.org/professionals/physician_gls/PDF/prostate. pdf. Accessed July 26, 2004.
27. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
28. Klienbaum DG, Kupper LL, Muller KE, et al. Applied regression analysis and other multivariable methods, 3rd ed. Pacific Grove, CA: Doxbury; 1998.
29. Food and Drug Administration. Zometa consumer information. Available from www.fda.gov/cder/consumerinfo/druginfo/zometa.htm. Accessed December 1, 2004.